Kamada (NASDAQ:KMDA) is scheduled to be announcing its Q3 earnings results before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of $0.09 per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.
NASDAQ:KMDA opened at $5.44 on Tuesday. The firm has a market capitalization of $214.20 million, a price-to-earnings ratio of 9.89 and a beta of 1.09. Kamada has a 1-year low of $4.63 and a 1-year high of $6.70. The company has a current ratio of 4.74, a quick ratio of 3.40 and a debt-to-equity ratio of 0.04. The business’s fifty day moving average price is $5.17 and its 200 day moving average price is $5.50.
Several research analysts recently weighed in on KMDA shares. ValuEngine raised Kamada from a “sell” rating to a “hold” rating in a research report on Monday. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Kamada in a research note on Wednesday, August 7th. Finally, Zacks Investment Research downgraded Kamada from a “hold” rating to a “sell” rating in a research note on Tuesday, August 13th.
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.
See Also: What is Blockchain?
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.